Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company ...

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a biopharmaceutical company specializing in the development of RNAi therapeutics, with a diverse pipeline and strong partnerships within the industry.

Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 [email protected] Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 [email protected] ...

What happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (NASDAQ: ARWR) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.

An Arrowhead Pharmaceuticals “gene-silencing” drug that the biotech has been quietly researching as a gout treatment will continue its development under a partnership with Horizon Therapeutics.

If so, you'll want to check out Arrowhead Pharmaceuticals (ARWR -6.03%). SVB Securities, a subsidiary of SVB Financial, recently gave the stock an upgrade to outperform and raised its price target.